AbbVie (ABBV) shares rallied in premarket trading after the company reported a strong first-quarter beat, exceeding analyst expectations for both earnings per share and revenue. First-quarter adjusted EPS came in at $2.65 per share against a consensus of $2.59, while total revenue reached $15 billion,...
AbbVie announced on Monday a definitive agreement to acquire Apogee Therapeutics for $10.9 billion, marking the company's largest buyout in over five years. The deal is strategically designed to strengthen AbbVie's immunology portfolio, specifically targeting inflammatory diseases such as atopic dermatitis and asthma, as it...
AbbVie (NYSE: ABBV) is positioned ahead of its July 31 Q2 earnings report with strong momentum driven by two blockbuster immunology drugs, Skyrizi and Rinvoq. These products combined generated $6.6 billion in revenue during the first quarter of 2026, effectively replacing Humira as the company's...
AbbVie (ABBV) reported strong financial performance in the second quarter of 2026, with total net revenues reaching $16.99 billion, a 10.2% increase year over year. This growth was driven primarily by its immunology and neuroscience franchises, specifically Skyrizi and Rinvoq, which generated a combined $8.03...
Cantor Fitzgerald has raised its price target for AbbVie (NYSE: ABBV) from $265 to $285, maintaining an overweight rating. This follows a mixed landscape of recent analyst actions, including JPMorgan Chase increasing its target to $280 and DZ Bank upgrading the stock to a strong...
Arbor Capital Management Inc. ADV established a new position in AbbVie Inc. (NYSE: ABBV) during the first quarter, purchasing 27,001 shares valued at approximately $5.63 million. This acquisition makes AbbVie the firm's largest holding, accounting for roughly 4.6% of its portfolio. Concurrently, several other major...
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic...
AbbVie reported record financial results at its annual meeting held on May 9, citing total net revenues of $61.2 billion that exceeded initial expectations by over $2 billion. CEO Rob Michael highlighted an all-time high for revenue driven by an 8.6% sales growth, which more...
AbbVie (ABBV) recently reported Q1 2026 revenue of $15 billion, surpassing the consensus estimate of $14.72 billion by $280 million and representing a 12.43% year-over-year increase. While GAAP net income fell 45.96% due to significant investment charges of $744 million in intellectual property research and...
AbbVie reported its financial results for the fourth quarter and full year 2025, highlighting record net sales achieved in the second full year following the loss of U.S. exclusivity for its key drug, Humira. Robert A. Michael, Chairman and CEO, described 2025 as an outstanding...
AbbVie Inc. reported first-quarter 2026 results that significantly exceeded analyst expectations, with adjusted earnings per share (EPS) of $2.65 and total net revenues reaching $15.0 billion, representing a 12.4% increase year-over-year. CEO Rob Michael described the performance as exceeding expectations across the diverse portfolio, while...
AbbVie Inc. (NYSE: ABBV) shares rose 1.4% to $256.80 following a price target upgrade from Canaccord Genuity, which raised its target from $273.00 to $282.00 while maintaining a buy rating. The stock reached an intraday high of $258.38 with trading volume declining 38% from the...
Andra AP fonden significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 44.2% during the first quarter, acquiring an additional 86,969 shares to bring its total holding to 283,811 shares valued at $61.7 million. This investment makes AbbVie the fund's 18th largest position, representing...
Adams Diversified Equity Fund Inc. reduced its position in AbbVie Inc. by 31.1% in the first quarter, selling 58,300 shares to hold a remaining stake of 129,400 shares valued at $28.1 million. While this major fund decreased its exposure, several smaller institutional investors including Chelsea...
في 23 يونيو 2026، أعلنت شركة AbbVie (ABBV) عن موافقات تنظيمية هامة تشمل الموافقة الكندية على عقار Boey لتحسين خطوط الوجه لدى البالغين، وهو أول نوع مصلي E معتمد من التوكسين العصبي البوتولينوم لهذا الغرض. كما وافقت المفوضية الأوروبية على عقار Maviret لعلاج عدوى فيروس...
AbbVie (NYSE: ABBV) is described as an underrated growth story with CEO Robert A. Michael reporting that the company exceeded expectations in Q1 2026. Despite shares trading at $221.59, down 1.43% year-to-date, revenue accelerated by 12.4% year-over-year. Immunology revenue specifically hit $7.29 billion, driven by...
AbbVie (ABBV) shares gained approximately 5% following the release of robust first-quarter fiscal 2026 results on April 29, which beat analyst estimates for both earnings per share and sales. The company further strengthened investor confidence by raising its full-year guidance for 2026, updating earnings per...
AbbVie Inc. shares approached a record high on September 24, 2026, trading at USD 265.07 after the company reported strong second-quarter financial results. The quarterly earnings per share (EPS) beat analyst consensus estimates by USD 0.04, reaching USD 3.65 against an expected USD 3.61. This...
AbbVie Inc. shares rallied to trade near their 52-week high of $267.47, reaching approximately $263.52 on September 21, 2026, following the announcement of a multi-year collaboration with Iambic. This partnership leverages artificial intelligence to accelerate small molecule drug discovery across AbbVie's key therapeutic areas, including...
The article argues that AbbVie (NYSE: ABBV) is the superior dividend investment compared to Pfizer, citing a longer history of dividend growth and stronger revenue expansion. While Pfizer offers a higher current yield at 6.1%, AbbVie provides a more sustainable profile with a Dividend King...
